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A B S T R A C T
Background
Despite the availability of several evidence-based therapies and non-pharmacological strategies to improve control of symptoms and
prevent exacerbations of asthma, patients with asthma continue to be at risk for mortality and morbidity.
Previous trials have demonstrated the potentially beneﬁcial effects of the long-acting muscarinic antagonist (LAMA) tiotropium on
lung function in patients with asthma; however, a deﬁnitive conclusion on the beneﬁt of LAMA in asthma is lacking, as is information
on where in the current step-wise management strategy they would be most beneﬁcial.
Objectives
To assess the efﬁcacy and safety of a LAMA added to any dose of an inhaled corticosteroid (ICS) compared with the same dose of ICS
alone for adults whose asthma is not well controlled.
Search methods
We searched the Cochrane Airways Group Specialised Register (CAGR) from inception to April 2015, and we imposed no restriction
on language of publication. We also searched clinicaltrials.gov, theWorld Health Organization (WHO) trials portal and drug company
registries to identify unpublished studies.
Selection criteria
We searched for parallel and cross-over randomised controlled trials in which adults whose asthma was not well controlled by ICS alone
were randomly assigned to receive LAMA add-on or placebo (both combined with ICS) for at least 12 weeks.
Data collection and analysis
Two review authors independently screened the searches and extracted data from study reports. We used Covidence for duplicate
screening, extraction of study characteristics and numerical data and risk of bias ratings. Pre-speciﬁed primary outcomes included
exacerbations requiring oral corticosteroids, quality of life and all-cause serious adverse events.
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Main results
We identiﬁed ﬁve studies that met the inclusion criteria. All studies applied a double-blind, double-dummy design, and the population
of all studies totalled 2563 adult participants. Study duration ranged from 12 weeks to 52 weeks, and risk of bias across domains in all
studies was low. Trials included more women than men (33% to 47% male), and mean age of participants ranged from 41 to 48 years.
Participants generally had a long history of asthma, and mean baseline predicted forced expiratory volume in one second (FEV1) was
between 72% and 75% in three studies reporting pre-bronchodilator values.
The rate of exacerbations requiring oral corticosteroids (OCS) was lower in patients prescribed an LAMA add-on than in those receiving
the same dose of ICS alone (odds ratio (OR) 0.65, 95% conﬁdence interval (CI) 0.46 to 0.93; 2277 participants; four studies; I2 =
0%; high-quality evidence), meaning that 27 fewer people per 1000 would have an exacerbation over 21 weeks requiring OCS with
LAMA compared with ICS alone (95% CI 42 fewer to 6 fewer).
All-cause serious adverse events (SAEs) and exacerbations requiring hospital admission were rare and the effects too imprecise to permit
ﬁrm conclusions, but effects suggested that LAMA add-on may be associated with fewer of both compared with ICS alone (SAEs: OR
0.60, 95% CI 0.23 to 1.57; 2532 participants; four studies; low-quality evidence; exacerbations requiring hospital admission: OR 0.42,
95% CI 0.12 to 1.47; 2562 participants; ﬁve studies; moderate-quality evidence). Additional therapy with a LAMA showed no clear
beneﬁt in terms of quality of life compared with ICS given alone; high-quality evidence showed only a small mean improvement in
quality of life as measured on the Asthma Quality of Life Questionnaire (AQLQ), which was not statistically signiﬁcant. The same was
true for asthma control as measured on the Asthma Control Questionnaire (ACQ), which was based on moderate-quality evidence.
LAMA combined with ICS showed consistent beneﬁt in a range of lung function measures compared with the same dose of ICS alone,
and LAMA was not associated with signiﬁcantly higher rates of adverse events than were reported with placebo.
Authors’ conclusions
For adults taking ICS for asthma without a long-acting beta -agonist (LABA), LAMA given as add-on treatment reduces the likelihood
of exacerbations requiring treatment with OCS and improves lung function. The beneﬁts of LAMA combined with ICS for hospital
admissions, all-cause serious adverse events, quality of life and asthma control remain unknown.
Results of this review, along with ﬁndings of related reviews conducted to assess the use of LAMA in other clinical scenarios involving
asthma, can help to deﬁne the role of LAMA in the management of asthma. Trials of longer duration (up to 52 weeks) would provide
a better opportunity to observe rare events such as serious adverse events and exacerbations requiring hospital admission.
P L A I N L A N G U A G E S U M M A R Y
Does adding a long-acting muscarinic antagonist (LAMA) to an inhaled steroid help people with uncontrolled asthma more
than an inhaled steroid alone?
Main point: People with poorly controlled asthma are less likely to have an asthma attack needing treatment with oral steroids if they
take a LAMA on top of their inhaled steroid. LAMA also improve lung function compared with inhaled steroids alone, but their beneﬁt
is uncertain for hospital admissions, serious adverse events, quality of life and asthma control.
Why is this question important?
Although lots of medicines are available to treat people with asthma, some patients remain at risk of dying when their disease is poorly
controlled. A class of inhaled drugs called long-acting beta2-agonists (LABA) are usually given as an add-on to people whose asthma is
not well controlled by inhaled steroids alone, and long-acting muscarinic antagonists (LAMA) are newer drugs now considered as an
alternative add-on for these patients.
How did we answer the question?
We looked for randomised controlled studies of at least 12 weeks that compared LAMA as an add-on to inhaled steroids versus inhaled
steroids alone. Two people searched through databases and websites, looked at all published and unpublished studies, and compiled a
list of studies that looked at the review question. The most recent searches were done in April 2015.
What did we find out?
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Over ﬁve months, fewer people using a LAMA required oral steroids for an asthma attack, and their lung function was improved over
that of patients taking inhaled steroids alone. It looked as though people taking LAMA might be less likely to have to go to the hospital
for an asthma attack or for another ’serious adverse event’, but we couldn’t be sure because the studies were short, and these things
did not happen very often in either group. A LAMA added to an inhaled steroid did not appear to improve people’s quality of life or
control of asthma symptoms.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
LAM A add-on compared with ICS alone for adults with asthma
Patient or population: adults with asthma not well controlled on ICS alone
Settings: out-pat ient
Intervention: LAMA add-on
Comparison: ICS alone
Time point: weighted mean durat ion of the studies included in each analysis
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
ICS alone LAM A add-on
Exacerbations requir-
ing oral corticosteroids
(OCS)
21 weeks
80 per 1000 53 per 1000
(38 to 74)
OR 0.65
(0.46 to 0.93)
2277
(4 RCTs)†
⊕⊕⊕⊕
High
LAMA benef it
Quality of life (AQLQ)
1 = severely impaired;
7 = not impaired at all
23 weeks
Mean AQLQscore in the
control group was 5.44
Mean AQLQscore in the
intervent ion group was
0.05 better (0.03 worse
to 0.12 better)
- 1713
(3 RCTs)
⊕⊕⊕⊕
Higha
MCID = 0.5
All- cause serious ad-
verse events
24 weeks
29 per 1000 18 per 1000
(7 to 45)
OR 0.60
(0.23 to 1.57)
2562
(5 RCTs)
⊕⊕©©
Lowb,c
Exacerbations requir-
ing hospital admission
24 weeks
6 per 1000 2 per 1000
(1 to 9)
OR 0.42
(0.12 to 1.47)
2562
(5 RCTs)
⊕⊕⊕©
Moderatec
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Lung function - trough
FEV1 (L, change from
baseline)
24 weeks
Mean change in trough
FEV1 in the control
group was -0.02 L
Mean trough FEV1 in the
intervent ion group was
0.14 higher (0.10 higher
to 0.17 higher)
- 2459
(5 RCTs)
⊕⊕⊕⊕
Highc,d
Asthma control (ACQ)
0 = no impairment;
6 = maximum impair-
ment
21 weeks
Mean ACQ total in the
control group was 1.47
Mean ACQ total in the
intervent ion group was
0.08 better (0.19 better
to 0.03 worse)
- 1916
(3 RCTs)
⊕⊕⊕©
Moderatea,e
MCID = 0.5
Any adverse events
24 weeks
506 per 1000 493 per 1000
(450 to 539)
OR 0.95
(0.80 to 1.14)
2562
(5 RCTs)
⊕⊕©©
Lowc,f
* The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based on
the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
†Only pooled data f rom the twin trials were available for this outcome and had to be entered under one study ID.
ACQ: Asthma Control Quest ionnaire; AEs: adverse events; AQLQ: Asthma Quality of Life Quest ionnaire; CI: conf idence interval; FEV1: f orced expiratory volume in 1 second;
ICS: inhaled cort icosteroid; LAM A: long-act ing muscarinic antagonist ; M CID: minimal clinically important dif f erence; OCS: oral cort icosteroid.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
aConf idence interval does not exclude the possibility of benef it f rom ICS alone, but both conf idence lim its are well below the
established MCID of 0.5 on these scales (no downgrade).
bI2 = 59%, P value = 0.05 (-1 inconsistency).
cOne study in this analysis allowed part icipants to cont inue taking combinat ion ICS/ LABA; therefore, some results were
derived f rom part icipants who do not meet all inclusion criteria for this review. The study accounted for a maximum of 26.7%
of the analysis weight, and mostly less than 20% (-1 indirectness).
dSome stat ist ical heterogeneity but not stat ist ically signif icant (no downgrade).
eI2 = 72%, P value = 0.03 (-1 inconsistency).
f Some studies reported ‘‘adverse events (all)’’ as those not classed as serious; therefore, this f igure taken alone may not
equal adverse events of all severit ies. In addit ion, it was sometimes possible to extract adverse event (AE) data f rom
clinicaltrials.gov only when AEs occurring in > 5% of part icipants were listed (-1 indirectness).
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B A C K G R O U N D
Description of the condition
Asthma is a “heterogeneous disease, usually characterised by
chronic airway inﬂammation. It is deﬁned by the history of respi-
ratory symptoms such as wheeze, shortness of breath, chest tight-
ness, and cough that vary over time and in intensity, together with
variable expiratory airﬂow limitation” (GINA 2014b). Common
triggers include allergens, pollutants and viral infections, although
endogenous factors have also been identiﬁed. The World Health
Organization (WHO) recognises the global burden of asthma
and estimates a worldwide prevalence of 300 million people of
all ages, with 250,000 people dying each year (WHO 2007).
Asthma prevalence is greater in urbanised communities, and with
the world’s urbanised population projected to grow from 45% to
59% by 2025, the number of people diagnosed with asthma is
predicted to increase by 100 million over this time (Global Burden
of Asthma Report 2004). Epidemiological data suggest that preva-
lence is greatest in the developed world, with prevalence amongst
adults at 8.2% in the USA (CDC 2014) and at 9% to 10% in the
UK (DOH 2012). Asthma presents a heavy ﬁnancial burden on
health services in the UK and worldwide (Global Asthma Report
2011), with theNational Health Service (NHS) spending a billion
pounds per year on treatment of patients with asthma (Asthma UK
2014). This considerable expense represents direct medical costs,
such as provision of medicines and frequent general practitioner
(GP) consultations, outpatient services and hospital admissions
due to poorly controlled disease (Barnes 1996). However, the eco-
nomic cost of asthma is worsened by indirect costs to the patient
resulting from time off work or school due to sickness and loss of
earnings due to morbidity and early mortality (Global Burden of
Asthma Report 2004).
Asthma can present with varying degrees of severity; in the most
severe cases, it can cause daily chronic symptoms and frequent
exacerbations (deﬁned as acute worsening of asthma symptoms).
Overarching principles of treatment focus on controlling daily
symptoms and preventing exacerbations.
Bronchodilating agents and corticosteroids delivered via inhaler
devices are the mainstay in asthma management. Short-acting
bronchodilating agents such as salbutamol are used on a “when re-
quired” basis as reliever therapy, and inhaled corticosteroids (ICSs)
are given regularly asmaintenance therapy.Other agents employed
in asthma management include inhaled long-acting bronchodilat-
ing beta2-agonists (LABA) and leukotriene-receptor antagonists
(taken as tablets). Treatment is introduced and is increased through
a step-wise approach, depending on the severity and frequency of
symptoms (BTS/SIGN 2012; GINA 2014a).
Description of the intervention
Asthma treatment is commenced at the level most likely to achieve
control of the patient’s symptoms; treatment is steppedup tomain-
tain this control and is stepped down when the patient’s condition
is stable and has been well maintained (BTS/SIGN 2012; GINA
2014a). Step 1 involves the use of a short-acting bronchodilating
agent alone on a when-required basis; patients who remain inad-
equately controlled are increased to step 2, with the introduction
of an inhaled corticosteroid (ICS) for regular use as maintenance
therapy. Regular daily therapy with an ICS is known to improve
lung function and symptom control while reducing airway in-
ﬂammation and use of reliever therapy compared with intermit-
tent use of an ICS (Chauhan 2013). However, if regular use of
an ICS at a low to medium dose does not maintain control of
the patient’s symptoms-that is, the patient suffers from recurrent
exacerbations or nocturnal awakening, or frequently uses reliever
therapy to relieve symptoms of breathlessness, chest tightness and
wheeze-a step up in treatment to step 3 is required. At step 3 in
the management guidelines, the addition of a long-acting beta2-
agonist (LABA) is recommended for adults, as this was found to
be superior to alternative treatments (Chauhan 2014: Ducharme
2010). Alternative therapies for people whose asthma is not well
controlled on low to medium doses of ICS and for whom a LABA
has not worked include introducing a daily leukotriene receptor
antagonist tablet or increasing the ICS dose (BTS/SIGN 2012;
GINA 2014a).
Long-acting muscarinic antagonists (LAMAs) are not currently
recommended in evidence-based guidelines for the treatment of
patients with asthma; only one LAMA preparation (Spiriva Respi-
mat 2.5 mcg) has had its licence extended for use in people with
asthma, and only for patients already taking combination LABA
and ICS who have had at least one severe exacerbation in the pre-
vious year (eMC 2014a). However, several other LAMA prepara-
tions are used frequently for the treatment of chronic obstructive
pulmonary disease (COPD). COPD, like asthma, is characterised
in part by airway obstruction, and patients beneﬁt from the bron-
chodilating effects of LAMA, which reduce airﬂow limitation and
improve symptoms (NICE 2010). Previous studies have demon-
strated that the LAMA tiotropium signiﬁcantly reduced the fre-
quency of exacerbations andhospital admissions related toCOPD,
and improved lung function and quality of life in patients with
COPD (Karner 2014).
How the intervention might work
Long-acting muscarinic antagonists act by inhibiting the effects
of acetylcholine at muscarinic (M)-receptors. When administered
via inhalation, they competitively antagonise M3-receptors, pre-
venting acetylcholine-mediated constriction of bronchial smooth
muscle. This permits dilation of the airways. Their slow disso-
ciation from local M3-receptors and prolonged half-lives mean
that such agents are administered only once or twice daily (EMC
2013a; EMC 2013b; EMC 2014b).
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Chronic obstructive pulmonary disease and asthma share similar
symptoms, namely, shortness of breath, chronic cough and wheeze
(BTS/SIGN 2012; NICE 2010). Regulation of airway smooth
muscle tone byM-receptors is enhanced and contributes to airﬂow
obstruction in bothCOPDand asthma (Gosens 2006). Therefore,
a reduction in M-receptor-mediated airway constriction would be
beneﬁcial in relieving these common symptoms of COPD and
asthma.
Previous studies and national guidelines for COPD have shown
that LAMA and LABA have comparable efﬁcacy in treating pa-
tients with moderate COPD (NICE 2010). LABA is also a bron-
chodilator and is the favoured treatment for introduction at step
3 or 4 of asthma management, when it is administered con-
comitantly with an ICS to improve control of symptoms (GINA
2014a). Although a LAMA mediates bronchial smooth muscle
relaxation in a manner different from that of a LABA, its bron-
chodilatory effect may be beneﬁcial for patients who require a step
up in their asthma management when ICS alone is insufﬁcient.
Why it is important to do this review
Although several evidence-based therapies and non-pharmacolog-
ical strategies are available to improve control of symptoms and
to prevent exacerbations of asthma, mortality due to asthma re-
mains a risk for patients. Asthma UK reported 1167 deaths due
to asthma in 2011, while “75% of hospital admissions for asthma
are avoidable and as many as 90% of the deaths from asthma
are preventable” (Asthma UK 2014). This highlights the fact that
current management of asthma remains suboptimal and indicates
that development of new management strategies and treatments
would be beneﬁcial.
As a result of the common features of COPD and asthma-such
as up-regulation of M-receptor-mediated airway tone and subse-
quent symptoms of breathlessness, cough and wheeze-known ben-
eﬁts of inhaled LAMA inCOPDmay also be beneﬁcial for patients
with asthma, particularly those with severe asthma whose con-
dition remains inadequately controlled by current recommended
step 3 therapy.
Previous trials have demonstrated the potentially beneﬁcial effects
of the LAMA tiotropium on lung function in patients with asthma
(Peters 2010; Vogelberg 2014). However, a deﬁnitive conclusion
on the beneﬁt of LAMA in asthma is lacking, as is information
explaining where in the current step-wise management strategy
theywould bemost beneﬁcial. Therefore, a systematic review of all
available randomised controlled trials on the addition of a LAMA
to an ICS would be beneﬁcial in revealing any beneﬁt to be derived
from the use of LAMA in asthma that remains uncontrolled by an
ICS alone.
Three associated reviews will assess the following.
• LAMA add-on compared with LABA add-on.
• LAMA add-on compared with increased ICS dose.
• LAMA add-on as triple therapy with LABA + ICS
compared with LABA + ICS alone.
O B J E C T I V E S
To assess the efﬁcacy and safety of a long-acting muscarinic an-
tagonist (LAMA) added to any dose of an inhaled corticosteroid
(ICS) compared with the same dose of ICS alone for adults whose
asthma is not well controlled.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included parallel and cross-over randomised controlled trials
(RCTs) of at least 12 weeks’ duration reported as full text, those
published as abstract only and those with unpublished data.
We did not exclude studies on the basis of blinding.
Types of participants
We included adults (aged 18 years or older) whose asthma was
not well controlled by ICS alone. We excluded trials that included
participants with chronic respiratory co-morbidities (e.g. COPD,
bronchiectasis).
If studies included adults and adolescents or children younger than
12 years and data are not reported separately, we included them if
the mean age in both groups was over 18 years.
Types of interventions
We included trials comparing a LAMA added to any dose of
ICS therapy versus continued use of ICS at the same dose. This
meant that studies in which participants were randomly assigned
to LAMA or placebo, with inclusion criteria specifying that par-
ticipants should be taking a stable dose of background ICS, were
included. We included studies that permitted the use of short-
acting medications (e.g. salbutamol, terbutaline, ipratropium) as
reliever therapy. We excluded trials in which a LABA was given
as part of the randomly assigned treatment and those in which
most participants continued their LABA alongside the randomly
assigned treatment. Studies involving the addition of any of the
following LAMA preparations were included.
• Tiotropium (Spiriva Handihaler or Respimat).
• Aclidinium bromide (Eklira Genuair).
• Glycopyrronium bromide (Seebri Breezhaler).
7Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with
asthma (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Types of outcome measures
Primary outcomes
• Exacerbations requiring oral corticosteroids.
• Quality of life (measured on a validated asthma scale, e.g.
Asthma Quality of Life Questionnaire).
• All-cause serious adverse events.
Secondary outcomes
• Exacerbations requiring hospitalisation.
• Lung function (in particular, trough forced expiratory
volume in one second (FEV1)).
• Asthma control (as measured on a validated scale, e.g.
Asthma Control Questionnaire, Asthma Control Test).
• Any adverse events.
Reporting by trial authors of one or more of the outcomes listed
here was not an inclusion criterion for the review.
If exacerbations were reported as a composite of more than one
deﬁnition (e.g. study participants with one or more exacerbations
requiring hospitalisation or an emergency department (ED) visit),
we analysed these separately.
Search methods for identification of studies
Electronic searches
We identiﬁed trials from the Cochrane Airways Group Specialised
Register (CAGR), which is maintained by the Trials Search Co-
ordinator for the Group. This Register contains trial reports iden-
tiﬁed through systematic searches of bibliographic databases, in-
cluding theCochrane Central Register of Controlled Trials (CEN-
TRAL), MEDLINE, EMBASE, the Cumulative Index to Nurs-
ing and AlliedHealth Literature (CINAHL), the Allied and Com-
plementary Medicine Database (AMED) and PsycINFO, and by
handsearching of respiratory journals andmeeting abstracts (please
see Appendix 1 for further details). We searched all records in the
CAGR using the search strategy provided in Appendix 2.
We also conducted a search of
ClinicalTrials.gov (www.ClinicalTrials.gov) and theWorld Health
Organization (WHO) trials portal (www.who.int/ictrp/en/). We
searched all databases from their inception to the present, and we
imposed no restriction on language of publication.
Searching other resources
We checked the reference lists of all primary studies and review
articles to look for additional references. We searched relevant
manufacturers’ websites for trials and other information.
We searched for errata or retractions from included studies pub-
lished in full text on PubMed (www.ncbi.nlm.nih.gov/pubmed)
on 9 April 2015.
Data collection and analysis
Selection of studies
UsingCovidence, two review authors (DA andKK) independently
screened titles and abstracts for inclusion of all potential studies
identiﬁed as a result of the search. We retrieved the full-text study
reports/publications; two review authors (DA and KK) indepen-
dently screened the full-text reports to identify studies for inclu-
sion, and identiﬁed and recorded reasons for exclusion of ineligible
studies. We will resolve disagreements through discussion or, if re-
quired, by consultation with a third person. We identiﬁed and ex-
cluded duplicates and collated multiple reports on the same study,
so that each study rather than each report was the unit of interest
in the review. We recorded the selection process in sufﬁcient detail
to complete a PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) ﬂow diagram and a Characteristics
of excluded studies table.
Data extraction and management
Weused a data collection form in Covidence that had been piloted
on at least one study in the review to document study character-
istics and outcome data. Both review authors (DA and KK) ex-
tracted the following study characteristics from included studies.
• Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and locations, study
settings, withdrawals and dates of study.
• Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria and exclusion criteria.
• Interventions: interventions, comparisons, concomitant
medications and excluded medications.
• Outcomes: primary and secondary outcomes speciﬁed and
collected and time points reported.
• Notes: funding for trial and notable conﬂicts of interest of
trial authors.
Two review authors (DA and KK) independently extracted out-
come data from included studies. We noted in the Characteristics
of included studies table if outcome data were not reported in a
useable way, and we resolved disagreements by discussion. One
review author (KK) transferred data into the Review Manager
(Review Manager 2014 (RevMan)) ﬁle. We double-checked that
data had been entered correctly by comparing data presented in
the systematic review versus those provided in study reports.
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Assessment of risk of bias in included studies
Two review authors (DA and KK) independently assessed risk of
bias for each study, using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved disagreements by discussion and assessed risk of bias
according to the following domains.
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective outcome reporting.
• Other bias.
We graded each potential source of bias as high, low or unclear and
provided a quote from the study report together with a justiﬁca-
tion for our judgement in the Risk of bias in included studies table.
We summarised risk of bias judgements across different studies for
each of the domains listed and considered blinding separately for
different key outcomes when necessary (e.g. for unblinded out-
come assessment, risk of bias for all-cause mortality may be very
different than for a patient-reported pain scale). When informa-
tion on risk of bias was related to unpublished data or correspon-
dence with a trial author, we noted this in the Risk of bias in
included studies table.
In cases for which the method of random sequence generation
or allocation concealment was not adequately described, but the
study was funded by amanufacturer with whommethods had pre-
viously been conﬁrmed, we assumed that the same methods were
applied. In the event of such insufﬁcient reporting, we contacted
the study author or sponsor to ask for additional information to
clarify uncertainties and to support our assumption that the same
methods were applied.
When considering treatment effects, we took into account the risk
of bias for studies that contributed to that outcome.
Assessment of bias in conducting the systematic
review
We conducted the review according to this published protocol and
reported deviations from it in the Differences between protocol
and review section of the systematic review.
Measures of treatment effect
We analysed dichotomous data as odds ratios, and continuous
data as mean differences or standardised mean differences. We en-
tered presented data as a scale with a consistent direction of effect.
We narratively described skewed data reported as medians and in-
terquartile ranges. When both raw data and adjusted analyses (e.g.
accounting for baseline differences) were presented, we used the
latter. When data published in peer-reviewed papers was different
from those given on clinicaltrials.gov, we cross-checked them (us-
ing generic inverse vairience (GIV) and RevMan analyses when
only mean difference vs placebo was available), and we contacted
study sponsor or trial authors to ask for more information if we
noted discrepancies in effects.
We undertook meta-analyses only when this was meaningful (i.e.
when treatments, participants and the underlying clinical question
were similar enough for pooling to make sense).
When multiple trial arms were reported in a single trial, we in-
cluded only the relevant arms. When two comparisons (e.g. drug
A vs placebo and drug B vs placebo) were combined in the same
meta-analysis, we halved the control group to avoid double count-
ing.
When both change from baseline and endpoint scores were avail-
able for continuous data, we used change frombaseline unlessmost
studies reported endpoint scores. If a study reported outcomes at
multiple time points, we used the end-of-study measurement.
When both an analysis using only participants who completed the
trial and an analysis that imputed data for participants who were
randomly assigned but did not provide endpoint data (e.g. last
observation carried forward) were available, we used the latter.
For dichotomous outcomes, we assumed equivalence of treatments
if the odds ratio estimate and its 95% conﬁdence interval were
between the pre-deﬁned arbitrary limits of 0.9 and 1.1.
Unit of analysis issues
For dichotomous outcomes, we used participants rather than
events as the unit of analysis (i.e. number of adults admitted to
hospital rather than number of admissions per adult).
Dealing with missing data
We contacted investigators or study sponsors to verify key study
characteristics and to obtain missing numerical outcome data
when possible (e.g. when a study was identiﬁed as an abstract
only). When this was not possible, and when missing data were
thought to introduce serious bias, we performed a sensitivity anal-
ysis to explore the impact of including such studies in the overall
assessment of results.
Assessment of heterogeneity
We used the I² statistic to measure heterogeneity among the trials
in each analysis. If we identiﬁed substantial heterogeneity (e.g. I
2 > 30%), we reported this and explored possible causes through
pre-speciﬁed subgroup analyses.
Assessment of reporting biases
We were not able to pool more than 10 trials, so we could not
examine a funnel plot to explore possible small-study and publi-
cation biases.
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Data synthesis
We used a random-effects model for all analyses, as we expected
variation in effects due to differences in study populations and
methods. We performed sensitivity analyses using ﬁxed-effect
models.
’Summary of findings’ table
We created Summary of ﬁndings for the main comparison to doc-
ument all primary and secondary outcomes listed in the protocol.
We used the ﬁve GRADE (Grades of Recommendation, Assess-
ment, Development and Evaluation) considerations (study limi-
tations, consistency of effect, imprecision, indirectness and pub-
lication bias) to assess the quality of a body of evidence as it re-
lates to studies that contributed data to the meta-analyses for pre-
speciﬁed outcomes. We applied methods and recommendations
as described in Section 8.5 and Chapter 12 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011) using
GRADEpro software (Brozek 2008). We justiﬁed all decisions to
downgrade or upgrade the quality of studies by using footnotes
and by making comments when necessary to aid the reader’s un-
derstanding of the review.
Subgroup analysis and investigation of heterogeneity
We planned the following subgroup analyses for primary out-
comes.
• Duration of therapy (≤ 6 months, > 6 months).
• Corticosteroid dose (according to GINA 2014, deﬁned as
low, medium and high cutoffs).
• Dose and type of LAMA (e.g. tiotropium HandiHaler 18
mcg, tiotropium Respimat 5 mcg).
We used the formal test for subgroup interactions provided in
Review Manager 2014 (RevMan).
Sensitivity analysis
We planned the following sensitivity analyses on primary out-
comes, with the following studies excluded.
• Unpublished data.
• Studies at high risk of bias for blinding (participants and
personnel).
We conducted an unplanned sensitivity analysis on primary out-
comes by removing one study in which around half of the par-
ticipants were taking a LABA, which was outside the inclusion
criteria.
R E S U L T S
Description of studies
Results of the search
We identiﬁed 71 records through electronic database searches and
obtained a further 122 records from additional resources (clinical-
trials.gov, reference lists of other publications and drug company
trial registries). Of the total 193, we identiﬁed 54 as duplicates
and screened the remaining 139. Upon screening titles and ab-
stracts, we excluded 105 that did not meet the inclusion criteria.
We excluded 22 of the remaining 34 records after retrieving and
inspecting full texts; these related to 20 studies. The main reasons
for exclusion were as follows: LABA were part of the randomly
assigned treatment (n = 6), the study was too short (n = 6) and the
wrong comparator was used (n = 5). The remaining 12 records
related to ﬁve studies that met all inclusion criteria and were in-
cluded in the qualitative synthesis. All ﬁve studies reported data
that could be included in at least one meta-analysis. Trial ﬂow is
shown in Figure 1.
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Figure 1. Study flow diagram.
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Included studies
Design and duration
We identiﬁed ﬁve studies that made the comparison of interest
and met the inclusion criteria. Details of study characteristics are
provided in Characteristics of included studies and in Table 1. All
studies were of a double-blind, double-dummy design, and the
population for all studies totalled 2563 adult participants. Dura-
tion of studies ranged from 12weeks to 52 weeks.Only the LAMA
plus ICS and placebo (ICS-only) groups in each study are rele-
vant to the present review and are considered herein. The LABA
plus ICS groups featured in NCT00350207, NCT01172821 and
NCT01172808 are considered in a related systematic review (see
Kew 2015).When further clariﬁcation of study design or outcome
analyses was required, we contacted study authors, who were able
to provide additional information and analyses.
Participant inclusion and exclusion criteria
Included participants were between 18 and 75 years of age at the
start of the study and had a three-month history of asthma, which
was ﬁrst diagnosed before the age of 40. Included participants were
symptomatic despite their current maintenance therapy, which
they had been using for at least four weeks before the trials began.
Participants included in the studies were able to correctly use all
inhaler devices randomly assigned to them and were able to carry
out all tests and procedures related to collating outcome measures.
Patients with a concomitant “signiﬁcant disease” were excluded
from the study. This was deﬁned by Boehringer Ingelheim as a
“disease which, in the opinion of the investigator, may (i) put the
patient at risk because of participation in the trial, or (ii) inﬂuence
the results of the trial, or (iii) cause concern regarding the patient’s
ability to participate in the trial; patients with a clinically relevant
abnormal screening (visit 1) haematology or blood chemistry if
the abnormality deﬁnes a signiﬁcant disease as deﬁned in exclusion
criterion no. 1”. Patients with very unstable asthma and requiring
in excess of 10 puffs of reliever therapy per day on two consecu-
tive days during the screening period were also excluded from the
trials, as were those with concomitant lung disease, arrhythmia or
recent history of heart failure or acute coronary disease (within the
previous 12 months and 6 months, respectively). Smokers and ex-
smokers who had stopped smoking the year before the trial com-
menced were also excluded from the studies.
Participant baseline characteristics
The mean age of participants and the proportion of males and
females in each study group were reported in all ﬁve included
studies. The mean ages of participants were between 41 and 48
years. The percentage of male participants remained consistently
less than half of the study population and ranged from 33.3% to
46.8%.
The mean percentage predicted FEV1 at baseline was between
72% and 75% in three studies reporting pre-bronchodilator val-
ues, and 91% and 94% across groups in the only study reporting
post-bronchodilator values (NCT01316380). Participants had a
long history of asthma, and the mean number of years since di-
agnosis ranged from 16 to 23 across groups in the four studies
reporting this measure.
Characteristics of the interventions
All of the studies included in this review compared the
use of tiotropium in addition to the pre-study ICS med-
ication versus the use of pre-study ICS medication alone.
All studies included tiotropium at a dose of 5 mcg daily,
and four of the ﬁve studies were multi-arm trials that
included separate arms receiving 2.5 mcg (low-dose) and
5 mcg (high-dose) of tiotropium daily (NCT01172808;
NCT01172821; NCT01316380; NCT01340209). All studies
delivered tiotropium via a Respimat inhaler. Matching placebo
Respimat inhalers were provided to participants randomly as-
signed to the placebo group.
Inhaled corticosteroids were not included as part of the ran-
domly assigned treatment but were speciﬁed as part of the inclu-
sion criteria of all studies. Inclusion criteria for NCT00350207
included treatment with 400 to 1000 mcg of budesonide or
equivalent. One study included only participants with at least a
four-week history of treatment with a low, stable dose of ICS
(NCT01316380). Remaining studies required at least a four-
week history of treatment with a medium, stable dose of ICS
(NCT01172808; NCT01172821; NCT01340209). However, in
NCT01340209, participants were included if they took ICS alone
or in ﬁxed combination with a LABA. We included this study be-
cause participants were not required to be taking the ICS/LABA
combination to be included in the trial, and the split between those
taking ICS alone (43%) and those given ICS alongside a LABA
(57%) was relatively even. Sensitivity analyses were performed to
remove this study from the primary outcomes. Participants in all
studies continued this usual maintenance dose of ICS throughout
the study period, including those taking LABA alongside ICS in
ﬁxed combination in NCT01340209. The actual ICS taken by
participants per day was not available in most studies. All studies
permitted the use of rescue beta-agonist medication during the
study period.
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Excluded studies
After viewing full texts, we excluded 13 studies. The main reasons
for exclusion included use of a LABA as part of the randomly as-
signed treatment and the requirement that participants take ICS/
LABA combination therapy if they were to be included in the trial
(n = 4 records, relevant to a separate review (Kew 2015)). Four
records were excluded because they used a comparator not rele-
vant to this review. Other reasons for exclusion were these: study
duration too short (i.e. duration < 12 weeks; n = 3 records), wrong
intervention used (n = 1 record) and wrong population examined
(n = 1 record). Excluded studies and reasons for exclusion are listed
in Characteristics of excluded studies.
Risk of bias in included studies
Overall, included studies showed highmethodological quality and
were largely given low risk of bias ratings (Figure 2).When insufﬁ-
cient information was available in published and publicly available
isources, we contacted the trial authors to ask for clariﬁcation of
methods used.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Information within the clinicaltrials.gov records or published re-
ports was generally insufﬁcient to warrant low risk of bias ratings,
but prior contact with study sponsors and additional contact for
this review conﬁrmed that standard practices were applied by study
sponsors (who used computerised codes and automated allocation
systems). For this reason, we judged all included studies to be at
low risk of selection bias.
Blinding
We rated all studies as having low risk of bias for blinding of
participants, personnel and outcome assessors. All studies were
designed to be double-blind and double-dummy, with the use of
matching placebo inhalers.
Incomplete outcome data
We rated all studies as having low risk of bias due to attrition.
Participant dropout was less than 10% in all groups within the
included studies. Investigators reported he numbers of participants
who were randomly assigned to a study arm but did not complete
the study, as well as the numbers of participants who provided data
for all outcome measures. They also provided reasons for non-
completion of the study.
Selective reporting
We originally rated two of the included studies as having high risk
of bias for selective reporting (NCT01172808, NCT01172821)
because the number of participants in each group who had an ex-
acerbation of asthma was not given, even though this was listed as
a secondary outcome measure. It was suggested that this was done
because “less than 50% of participants in each treatment group ex-
perienced an asthma exacerbation”. Also in relation to “all adverse
events” reported by these two studies, researchers reported only
adverse events experienced by at least 5% of the study population,
which led to an apparent underestimation of the magnitude of
all adverse events experienced. Both of these issues were resolved
when the full text was published in a peer-reviewed journal, so we
assessed all studies as having low risk of bias for selective reporting.
Other potential sources of bias
We deemed one study to have unclear risk of bias due to another
potential source. This involved an imbalance in the number of
participants in each study arm who had never smoked and was
considered to present potential risk for study outcomes. We noted
no issues with the other four studies and consequently rated them
as having low risk of bias.
Effects of interventions
See: Summary of findings for the main comparison LAMA
add-on compared with ICS alone for adults with asthma
Primary outcomes
Exacerbations requiring oral corticosteroids
LAMA reduced the odds that participants would need to take oral
corticosteroids (OCS) for an exacerbation of asthma compared
with those for ICS alone (odds ratio (OR) 0.65, 95% conﬁdence
interval (CI) 0.46 to 0.93; participants = 2277; four studies; I2 =
0%). As shown in Figure 3, this means that 27 fewer people per
1000 would require an OCS for an exacerbation longer than 21
weeks if they took a LAMA rather than an ICS alone (95% CI 42
fewer to 6 fewer). Data for the twin trials (NCT01172808 and
NCT01172821) were available only as a pooled result, so they had
to be entered as one study. We rated the evidence as high quality.
15Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with
asthma (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 3. Cates plot showing the absolute effect for the primary outcome.In the control group (ICS alone),
80 out of 1000 people had exacerbations requiring oral corticosteroids over 21 weeks, compared with 53 out of
1000 people for the intervention group (95% CI 38 to 74)(LAMA add-on). As such, in this time period, 27 fewer
people taking LAMA add-on would have had an exacerbation requiring oral corticosteroids than if they
continued taking ICS alone.
As a supplementary post hoc analysis, we looked at events coded
as ’asthma’ in the non-serious adverse events tables using Med-
DRA (Medical Dictionary for Regulatory Activities) terminology..
The sort of asthma events that would have been counted under
this term is not clear, so ﬁndings are difﬁcult to interpret, but all
studies reported data in this way. Fewer ’adverse events classiﬁed
as asthma’ were reported for groups taking LAMA than for those
who did not, although the conﬁdence interval showed no differ-
ence (OR 0.85, 95% CI 0.69 to 1.05; participants = 2561; ﬁve
studies; I2 = 0%). Risk of bias assessments and unpublished data
sensitivity analyses were not necessary, but we performed a sensi-
tivity analysis after removing NCT01340209 - the study in which
some participants continued to take a long-acting beta2-agonist
- and found that results were largely similar (OR 0.87, 95% CI
0.70 to 1.10; participants 2276; four studies; I2 = 0%). We graded
the quality of evidence for this analysis as low after downgrading,
because only a small population contributed data to this analysis,
only two of the ﬁve included studies measured this outcome and
poor deﬁnitions were provided for exacerbations requiring OCS
in each of these studies.
Quality of life
Scores on the AsthmaQuality of Life Questionnaire (AQLQ)were
slightly higher for those taking a LAMA than for those continuing
on ICS alone, but conﬁdence intervals showed beneﬁt for both
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treatments and were not within the range of the scale’s established
minimal clinically important difference (MCID) of 0.5 (MD0.05,
95% CI -0.03 to 0.12; participants = 1713; three studies; I2 =
0%). None of the planned sensitivity analyses could be performed
on this outcome (no studies at high risk of bias, no unpublished
data and no outcomes reported by the partial ICS/LABA study
(NCT01340209)). We graded evidence for this outcome as high
in quality.
All-cause serious adverse events
People in these studies who were taking LAMA reported fewer
serious adverse events, but the pooled effect was too inconsistent
and imprecise to suggest a deﬁnitive beneﬁt over ICS alone (OR
0.60, 95% CI 0.23 to 1.57; participants = 2562; ﬁve studies; I
2 = 59%). Given the heterogeneity, we performed a sensitivity
analysis using a ﬁxed-effect model, which increased the precision
of the estimate, suggesting fewer serious adverse events in people
taking LAMA add-on. As with exacerbations requiring OCS, we
performed a sensitivity analysis after removing NCT01340209;
the magnitude of the effect was reduced, as was heterogeneity,
but it remained similarly imprecise (OR 0.87, 95% CI 0.37 to
2.05; participants = 2277; ﬁve studies; I2 = 27%). This outcome
was downgraded to low quality as the result of heterogeneity and
inclusion in NCT01340209 of some participants taking a LABA.
Secondary outcomes
Exacerbations requiring hospitalisation
A total of nine people required hospital admission for an asthma
exacerbation during study periods, which meant that the estimate
was imprecise because few events were reported (OR 0.42, 95%
CI 0.12 to 1.47; participants = 2562; ﬁve studies; I2 = 0%). The
effect included no beneﬁt due to this imprecision but fewer hospi-
tal admissions with LAMA add-on. We also downgraded this out-
come because some participants in NCT01340209 did not meet
the inclusion criteria.
Lung function
Forced expiratory volume in one second (FEV1)
Trough FEV1 measurements improved by an additional 140 mL
in people taking LAMA add-on compared with those given ICS
alone (mean difference (MD) 0.14 mL, 95% CI 0.10 to 0.17;
participants = 2459; ﬁve studies; I2 = 26%). People who had been
taking LAMA add-on also had much improved peak FEV1 mea-
surements (MD0.19 L, 95%CI 0.15 to 0.23; participants = 1923;
three studies; I2 = 39%). Both analyses showed a degree of incon-
sistency between study results, but this ﬁnding was not statisti-
cally signiﬁcant. We rated the evidence for this outcome as high
in quality.
Peak expiratory flow (PEF)
Trough measurement of PEF was almost 30 L/min better in peo-
ple taking LAMA add-on (MD 28.07 L/min, 95% CI 22.51 to
33.64; participants = 2456; ﬁve studies; I2 = 24%), and again some
heterogeneity between study results was evident.
Forced vital capacity (FVC)
People taking a LAMA showed trough FVC improvements 90 mL
greater than those found in people not taking a LAMA (MD 0.09,
95% CI 0.05 to 0.13; participants = 2002; four studies; I2 = 8%),
and the result for peakmeasurementswas of similarmagnitude and
precision (MD 0.11, 95% CI 0.08 to 0.15; participants = 1922;
three studies; I2 = 6%). Both analyses revealed a small amount of
statistical heterogeneity.
Asthma control
Participants taking LAMA add-on improved slightly more on the
Asthma Control Questionnaire (ACQ) than those taking ICS
alone, but conﬁdence intervals for the effect showed no difference
and heterogeneity was signiﬁcant (MD -0.08, 95% CI -0.19 to
0.03; participants = 1916; three studies; I2 = 72%). Results and
conﬁdence intervals also fall well below the scale’s MCID of 0.5.
We downgraded to moderate the quality of the evidence used to
assess differences in ACQ scores because results were inconsistent.
The same studies and one other reported the number of people
who improved by at least the MCID (ACQ ’responders’). Using
this dichotomy, people in the LAMA group weremore likely to ’re-
spond’ than those taking continued ICS, but the conﬁdence inter-
vals did not rule out the possibility that ICS alone was better, and
signiﬁcant variation between studies was noted (OR 1.23, 95%
CI 0.87 to 1.74; participants = 2009; three studies; I2 = 69%).
Any adverse events
People taking LAMA add-on did not have a signiﬁcantly different
number of adverse events of any kind compared with those given
ICS alone (OR 0.95, 95% CI 0.80 to 1.14; participants = 2562;
ﬁve studies; I2 = 0%). This outcome was graded as low in quality
because some participants were taking LABA in NCT01340209,
and because some studies reported only adverse events that oc-
curred in at least 5% of participants.
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Subgroup analyses
Duration of therapy
All of the studies reporting exacerbations requiring OCS and the
three studies reporting quality of life on the AQLQ were less than
six months in duration, so it was not possible to perform a sub-
group analysis by duration for these two primary outcomes. These
outcomes also showed no important statistical heterogeneity, so it
was not necessary to investigate effect modiﬁers.
A subgroup analysis by study duration for the remaining primary
outcome - all-cause serious adverse events - showed a signiﬁcant
difference between the pooled result for the four shorter trials and
the one-year-long trial (I2 = 80%; P value = 0.03). This must be
interpreted with caution because of the observational nature of
subgroup analyses, and because only one trial was included in one
of the subgroups.
Corticosteroid dose
No statistical heterogeneity was noted between studies reporting
exacerbations requiring OCS, so comparisons in a steroid dose
subgroup analysis were meaningless. The three studies reporting
quality of life on theAQLQusedmediumdoses of inhaled steroids,
so no comparison could be made.
We split studies reporting the remaining primary outcome - all-
cause serious adverse events - into low-dose (NCT01316380) and
medium-dose (NCT00350207; NCT01172808;
NCT01172821; NCT01340209) subgroups. NCT00350207 al-
lowed doses up to 1000 mcg budesonide equivalent (high dose),
but these were classiﬁed as medium dose, as more of the range fell
under themedium dose category (400 to 800mcg). Heterogeneity
within the outcome was not accounted for by differences in ICS
dose (heterogeneity within the medium-dose subgroup remained
signiﬁcant).
Dose and type of LAMA
All included studies used tiotropium Respimat as their LAMA,
and all but one study included two dose groups that were merged
in the main comparison. To compare these, we separated out the
dose groups and compared them against the same control group,
while adjusting for double counting in each analysis. Tests for
subgroup differences did not suggest differences between the two
doses for any of the primary outcomes (Analysis 2.2).
In addition to the planned subgroup analysis, we performed a
direct comparison of the two doses using the four studies in which
this was possible (all but NCT00350207). The effect estimate
was too imprecise for review authors to conclude whether one
dose was better than another for reducing exacerbations requiring
OCS (Analysis 3.1). Direct dose comparisons for quality of life on
the AQLQ (Analysis 3.2) and for all-cause serious adverse events
(Analysis 3.3) did not suggest differences in effect for the two
doses.
Sensitivity analyses
Studies at high risk of bias for blinding of participants and
personnel
Weratednone of the studies as havinghigh risk of bias for blinding.
Unpublished data (i.e. no peer-reviewed full paper available)
No conference abstracts were included, and all data included in
the primary outcomes were available in peer-reviewed reports or
on publicly available websites.
D I S C U S S I O N
Summary of main results
Five studies met the inclusion criteria; all were double-blind, dou-
ble-dummy randomised controlled trials and ranged in length
from 12 to 52 weeks. We included in this review data from 2563
participants; we conducted this review to compare the use of in-
haled corticosteroid (ICS) only versus tiotropium (LAMA) 2.5
mcg or 5 mcg daily in addition to ICS therapy. Participants in all
included studies continued their pre-study maintenance dose of
ICS throughout the study period, which ranged from low dose
to high dose. More women than men were included in the trials
(33% to 47%male), and mean age of participants ranged from 41
to 48 years. Participants generally had a long history of asthma,
and mean baseline percentage predicted FEV1 was between 72%
and 75% in three studies reporting pre-bronchodilator values. All
studies reported good methods and were considered to be at low
risk of bias for most of the assessed domains (Figure 2).
High-quality evidence shows that the rate of exacerbations requir-
ing oral corticosteroids (OCS) was signiﬁcantly lower in patients
prescribed a LAMA add-on (27 fewer per 1000 participants, 95%
CI 6 fewer to 42 fewer) than in those receiving the same dose of
ICS alone.
Similarly, four fewer people per 1000 participants would have
an exacerbation resulting in hospitalisation if prescribed a LAMA
add-on compared with the same dose of ICS alone; this result
was not statistically signiﬁcant, with a conﬁdence interval ranging
from ﬁve fewer to three more people (per 1000) having such an
exacerbation. Eleven fewer people (per 1000) would experience a
serious adverse event when receiving a LAMA add-on; however,
the conﬁdence interval ranged from 22 fewer people to 16 more
people experiencing a serious adverse event with the addition of
LAMA therapy andhighlighted the imprecision of this result. Such
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events were relatively rare among the study population; this may
have been exacerbated by the short study period described in four
of the ﬁve included studies (< six months).
The addition of LAMA therapy did not show clear beneﬁt for
quality of life compared with ICS alone; high-quality evidence of
only a small mean increase in quality of life score (AQLQ) was not
statistically signiﬁcant. The same was true for asthma control as
measured on the ACQ, which was based on evidence of moderate
quality.
Addition of a LAMA led to signiﬁcant improvement in lung func-
tion compared with the same dose of ICS alone, with FEV1 in-
creased by 0.14 L. Evidence used to evaluate this outcome was
graded as high, despite slight heterogeneity and inclusion of data
from only one study, which also recruited patients who were using
a stable maintenance dose of LABA with ICS and permitted its
use throughout the study period. LAMA was not associated with
signiﬁcantly higher rates of adverse events than were reported with
placebo.
Overall completeness and applicability of
evidence
The evidence base included in this review was lacking in several as-
pects. All included studies used tiotropium at a dose of 5mcg daily
(licensed dose) or 2.5 mcg daily; therefore, we cannot determine
whether the results of this study apply to all other LAMA agents,
such as glycopyrronium or aclidinium bromide, which, although
not currently indicated for asthma, may be used to treat patients
with asthma in the future. Included studies were designed to com-
pare LAMA versus placebo, both combined with the usual ICS
dose, but did not detail which ICS participants had used. There-
fore, we cannot determine if the results of this study are affected
by ICS choice. Study populations included participants using low,
medium and high doses of ICS. Therefore, we cannot disregard
the fact that this variation in ICS dose may have contributed to
observed analyses, although the proportions of particpants using
low, medium and high doses of ICS were consistent in both study
arms.
All studies included in this review were industry-sponsored trials
that were conducted to a very high standard and in a controlled
manner. However, this scenario may not truly reﬂect normal prac-
tice, for example, in relation to patient concordance with therapy,
which may vary widely in general practice.
This study analysed the effects of LAMA add-on therapy on the
frequency of all-cause serious adverse events and exacerbations re-
sulting inhospital admission. Such eventswere relatively rare in the
study populations, and no signiﬁcant reduction in the frequency
of these outcome measures was found. This may reﬂect inclusion
only of patients at step 2 of asthma management (BTS/SIGN
2012), whose disease was not so severe that exacerbations often
resulted in hospital admission; however, the low frequency of such
events may have been exacerbated by the relatively short duration
of the included studies. The beneﬁt of LAMA add-on in reducing
all-cause serious adverse events was more pronounced in the only
included study lasting longer than six months; therefore, future
studies assessing these outcome measures in a similar population
would beneﬁt from longer trial duration for more accurate assess-
ment of the effects of LAMA add-on therapy.
Use of LAMA in themanagement of asthma is relatively new, with
only one UK license extension granted for Spiriva Respimat. The
licensed indication is only for use as triple therapy for patients
already receiving maintenance therapy with a LABA and 800 mcg
of budesonide or equivalent, who have had a least one severe ex-
acerbation in the previous year. This group of patients is different
from those considered in this review, but the study of LAMA in
patients with less severe asthma suggests that further license exten-
sions may be forthcoming. We hope that future versions of this
review will provide more powerful and applicable ﬁndings on the
use of LAMA for patients with less severe asthma.
Quality of the evidence
We rated evidence for one of the primary outcome measures -
exacerbations requiring treatment with OCS - as high in quality.
Although we included only 137 events in the analysis, we did not
consider the effect imprecise, and we included data for more than
2200 people from four multi-centre studies. We rated asthma-
related quality of life on the AQLQ as high.
We downgraded evidence for all-cause serious adverse events to
low quality as the result of inconsistency and indirectness, the lat-
ter because the study (NCT01340209) included participants us-
ing an ICS, as well as those using an ICS/LABA in a ﬁxed combi-
nation, and did not present results separately for these two groups
of patients. Thus, results from participants who did not meet the
inclusion criteria for this review have been included and reduce
the reliability of the results. This is also true for exacerbations re-
sulting in hospitalisation, lung function and all adverse events.
We downgraded the evidence for asthma control (ACQ total) to
moderate because of signiﬁcant inconsistency.
We downgraded the quality of the analysis of all adverse events
to low, in part because of indirectness of the trial, which included
some participants taking LABA/ICS, and because some of the
included trials were available only on clinicaltrials.gov, which lists
only adverse events experienced by a minimum of 5% of the study
population.
Potential biases in the review process
We conducted this review in accordance with the standards set by
MECIR 2013 and in keeping with the protocol (Allison 2014).
We have reported deviations from the protocol in the section titled
Differences between protocol and review.
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We conducted an additional sensitivity analysis to exclude one
trial, which included participants taking a LABA in addition to a
stable ICS dose before and during the study period.
As deﬁnitions for reported adverse events related to asthma were
lacking in these studies, along with details on whether such exac-
erbations required oral corticosteroids, we conducted an analysis
of all adverse events due to asthma.
A skilled information specialist conducted the main electronic
searches; thus it is unlikely that any relevant, qualifying studies
or trials have been overlooked for inclusion in this review. We
supplemented the main searches with searches of other sources
(pharmaceutical company clinical trial registries and reference lists
of associated studies and reviews), in addition to those required by
MECIR 2013 (i.e. clinicaltrials.gov, World Health Organization
(WHO) trials portal). We attempted to contact the authors of any
trials from which were we required additional data or clariﬁcation
of methods.
Agreements and disagreements with other
studies or reviews
Use of LAMA in the management of asthma has been reviewed in
many studies. Timmer et al. found that tiotropium, at doses of 5
mcg daily or 2.5 mcg twice daily, resulted in signiﬁcant improve-
ment in all measures of lung function compared with placebo,
when added to medium-dose ICS for patients with asthma, with a
signiﬁcant increase in adverse events (Timmer 2014). This is con-
sistent with the ﬁndings of other studies (Beeh 2014) and system-
atic reviews, some of which also highlighted the beneﬁt of LAMA
added on to other standard asthma treatments, such as ICS/LABA
combination therapy, when the disease is inadequately controlled
(Befekadu 2014; Rodrigo 2015; Tian 2014). Rodrigo et al. iden-
tiﬁed that tiotropium add-on to ICS not only signiﬁcantly im-
proved lung function but also signiﬁcantly reduced the rate of ex-
acerbations and improved asthma control (Rodrigo 2015).
One study comparing the efﬁcacy of tiotropium versus a LABA
found that tiotropium at a dose of 18 mcg daily was comparable
with salmeterol at a dose of 50 mcg twice daily when added to
medium-dose ICS (Peters 2010). This is consistent with ﬁndings
of other systematic reviews and a related Cochrane review under-
taken to assess the same hypothesis (Kew 2015; Rodrigo 2015).
This evidence supports the use of tiotropium as a bronchodilator
in the management of asthma; however, further research is needed
to determine the efﬁcacy of other LAMA drugs, and oﬂong-term
treatment, as most available evidence has been provided by studies
four to 14 weeks in duration. The results of this review are not
consistent with the evidence because these studies were only four
weeks in duration, and data may reﬂect only temporary, short-
term improvement in symptoms associated with LAMA use; all
studies included in this review have a minimum duration of 12
weeks, and results may highlight the fact that these short-term
improvements in disease state are not maintained.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
For patients taking ICS without a LABA, LAMA used as add-
on therapy reduces the likelihood of exacerbations requiring treat-
ment with OCS and improves lung function. Beneﬁts of LAMA
combined with ICS, including hospital admissions, all-cause se-
rious adverse events, quality of life and asthma control, have not
been ascertained.
Implications for research
Results of this review, along with those of related reviews assess-
ing the use of LAMA in other clinical scenarios of asthma, will
help to deﬁne the role of LAMA in the management of asthma.
This review should be updated as results from ongoing trials are
released. Trials of longer duration would provide better opportu-
nities to observe rare events, such as serious adverse events and
exacerbations requiring hospital admission.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
NCT00350207
Methods Study design: randomised controlled trial
Study grouping: parallel group
Open label: no
Cluster RCT: no
Participants Baseline characteristics
LAMA add-on
• N randomly assigned: 128
• N completed: 120
• Mean age, years (SD): 43.5 (12.6)
• % Male: 35.9
• % Predicted FEV1 (SD): 74.1 (16.1)
• % White: 93.0
• Duration of asthma, years (SD): 18.1 (12.1)
ICS alone
• N randomly assigned: 126
• N completed: 119
• Mean age, years (SD): 44.0 (11.9)
• % Male: 40.5
• % Predicted FEV1 (SD): 75.3 (19.0)
• % White: 92.1
• Duration of asthma, years (SD): 17.3 (12.3)
Inclusion criteria: patients homozygous for arginine at the 16th amino acid position of
the beta2-adrenergic receptor (B16 Arg/Arg); informed consent form; male and female
out-patients 18 to 65 years of age; documented history of asthma; current non-smokers
or ex-smokers with a cigarette smoking history < 10 pack-years; maintenance treatment
with inhaled corticosteroids with a total daily dose of 400 to 1000 mcg budesonide or
equivalent
Exclusion criteria: signiﬁcant disease other than asthma; recent history (i.e.≤ 6months)
of myocardial infarction; hospitalisation for heart failure within the past year; any unsta-
ble or life-threatening cardiac arrhythmia, or cardiac arrhythmia requiring intervention
or a change in drug therapy within the past year; malignancy for which the patient has
undergone resection, radiation therapy or chemotherapy within the past 5 years (treated
basal cell carcinoma allowed); COPD; history of life-threatening pulmonary obstruc-
tion, cystic ﬁbrosis or bronchiectasis; known active TB; thoracotomy with pulmonary
resection; current or recent (6 weeks) pulmonary rehabilitation
Interventions Intervention characteristics
LAMA add-on
• ICS type/dose: 400 to 1000 mcg of budesonide/equivalent
• Add-on type/dose: tiotropium 2 × 2.5 mcg daily in the evening (with salmeterol-
matching placebo twice daily)
• Co-medications: ICS regimens were maintained throughout the trial.
Concomitant respiratory medications were not allowed. Salbutamol metered-dose
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NCT00350207 (Continued)
inhaler (MDI) (100 mcg per puff ) as needed
• Type of inhaler: Respimat with MDI placebo
• Duration of treatment: 16 weeks
Placebo (ICS alone)
• ICS type/dose: 400 to 1000 mcg of budesonide/equivalent
• Co-medications: ICS regimens were maintained throughout the trial.
Concomitant respiratory medications were not allowed. Salbutamol metered-dose
inhaler (100 mcg per puff ) as needed
• Type of inhaler: Respimat placebo (and MDI placebo to blind salmeterol arm)
• Duration of treatment: 16 weeks
Participants were also randomly assigned to a third group, salmeterol add-on, which was
not relevant to this review
Outcomes Continuous
• Trough FEV1 (L)
• Asthma control (ACQ)
• Morning PEF (L/min)
• Trough FVC (L)
• Quality of life (Mini-AQLQ)
Dichotomous
• Any adverse events
• All-cause serious adverse events (SAEs)
• Exacerbations requiring oral corticosteroids
• Exacerbations requiring hospital admission
Identiﬁcation Sponsorship source: Boehringer Ingelheim, with collaboration from Pﬁzer
Country: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Italy, Russia,
Slovakia, South Africa, Spain, Turkey, UK
Setting: 109 investigational sites in 14 countries
Comments: none
Authors’ names: Leonardo Fabbri (corresponding), Eric D. Bateman (ﬁrst author)
Institution:Cape Town, South Africa; Frankfurt and Biberach, Germany; and Modena,
Italy
Email: leonardo.fabbri@unimore.it
Address: Bateman: Department of Medicine, University of Cape Town; Fabbri: Section
of Respiratory Diseases, University of Modena and Reggio Emilia
Notes Adverse outcomes: extracted asthma serious adverse events as ’Exacerbations requiring
hospital admission’. On clinicaltrials.gov, SAEs are deﬁned as follows: “Serious Adverse
Events include adverse events that result in death, require either inpatient hospitalisa-
tion or the prolongation of hospitalisation, are life-threatening, result in a persistent or
signiﬁcant disability/incapacity or result in a congenital anomaly/birth defect”
Adverse events are deﬁned on clinicaltrials.gov as not including SAEs
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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NCT00350207 (Continued)
Random sequence generation (selection
bias)
Low risk At visit 2, participants were randomly as-
signed (1:1:1 ratio) to placebo, tiotropium
or salmeterol. Randomisation was done in
blocks of 3 with no stratiﬁcation. The ran-
domisation schedule was generated by a
validated system (PMX CTM Release 3.3.
0 HP2; Propack Data GmbH, Karlsruhe,
Germany)
Allocation concealment (selection bias) Low risk Reports did not describe whether the ran-
domisation system included a function to
conceal the allocation scheme, but prior
contact with trial sponsors conﬁrmed the
allocation methods used
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “blinding was achieved with a double-
blind, double-dummy design with match-
ing placebos”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “blinding was achieved with a double-
blind, double-dummy design with match-
ing placebos”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was between 4.5% and 6.2%
across groups. All but 1 participant
(placebo group) were included in the efﬁ-
cacy analyses through imputation
Selective reporting (reporting bias) Low risk Outcomes were well reported in the pub-
lished paper and fully on clinicaltrials.gov
Other bias Unclear risk Demographic characteristics were well
balanced across treatment groups, with
slightly more female patients in the
tiotropium group and slightly more pa-
tients who had never smoked in the salme-
terol group
Sponsor and collaborator was Boehringer
Ingelheim,manufacturer of the tiotropium
inhaler used (Spiriva Respimat)
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NCT01172808
Methods Study design: Randomised controlled trial
Study grouping: parallel group
Open label: no
Cluster RCT: no
Participants Baseline characteristics
LAMA add-on (low)
• N randomly assigned: 262
• N completed: 249
• Mean age, years (SD): 43.7 (13.1)
• % Male: 40.5
• % Predicted FEV1 (SD): 73.1 (8.6)
• % White: NR
• Duration of asthma, years (SD): 22.2 (14.1)
LAMA add-on (high)
• N randomly assigned: 264
• N completed: 241
• Mean age, years (SD): 44.4 (12.6)
• % Male: 41.7
• % Predicted FEV1 (SD): 72.2 (8.2)
• % White: NR
• Duration of asthma, years (SD): 22.9 (14.7)
Placebo (ICS alone)
• N randomly assigned: 269
• N completed: 248
• Mean age, years (SD): 42.5 (13.1)
• % Male: 38.3
• % Predicted FEV1 (SD): 73.0 (8.2)
• % White: NR
• Duration of asthma, years (SD): 20.2 (13.4)
Inclusion criteria: informed consent; males and females 18 to 75 years of age; ≥ 3-
month history of asthma at enrolment; diagnosis before 40.5 years of age, conﬁrmed
by FEV1 increase ≥ 12% and ≥ 200 mL after salbutamol; on maintenance treatment
with a medium, stable dose of ICS ≥ 4 weeks; ACQ (≥ 1.5) before randomisation;
pre-bronchodilator FEV1 60% to 90% of predicted normal at screening; variation in
absolute FEV1 at screening (pre-bronchodilator) as compared with visit 2 (pre-dose)
within ± 30%; non-smoker ≥ 1 year with history < 10 pack-years; ability to use inhalers
and perform trial procedures correctly
Exclusion criteria: lung disease or signiﬁcant medical illness other than asthma; clini-
cally relevant abnormal screening, haematology or blood chemistry; hospitalisation for
cardiac failure during the past year; any unstable or life-threatening cardiac arrhythmia;
known active TB; resection, radiation or chemotherapy within 5 years for malignancy
(treated basal cell carcinoma allowed); thoracotomy with pulmonary resection; signiﬁ-
cant alcohol or drug abuse within 2 years; current or recent (6 weeks) pulmonary reha-
bilitation; known hypersensitivity to study drugs or any other components of delivery
systems; pregnant or nursing women; women of childbearing potential not using effec-
tive birth control; investigational drug, beta-blockers, tiotropium, oral or patch beta-
adrenergics, oral corticosteroids or “experimental” drugs for asthma not recommended
by international guidelines within 4 weeks; anti-IgE antibodies, e.g. omalizumab, within
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6 months; cromone, methylxanthines or PDE4 inhibitors within 2 weeks; asthma ex-
acerbation or respiratory tract infection within 4 weeks; previous random assignment
in this trial or in the respective twin trial (NCT01172821), or current participation in
another trial
Interventions Intervention Characteristics
LAMA add-on (low)
• ICS type/dose: Not part of randomised treatment, participants continued their
medium dose of usual ICS
• Add-on type/dose: Tiotropium 2.5 mcg once daily (evening)
• Comedications: All, participants were taking maintenance treatment with a
medium, stable dose of inhaled corticosteroids for at least 4 weeks prior to Visit 1
• Type of inhaler: Respimat (+ HFA MDI placebo twice daily to blind for salmeterol)
• Duration of treatment: 24 weeks
LAMA add-on (high)
• ICS type/dose: Not part of randomised treatment, participants continued their
medium dose of usual ICS
• Add-on type/dose: Tiotropium 5 mcg once daily (evening)
• Comedications: All, participants were taking maintenance treatment with a
medium, stable dose of inhaled corticosteroids for at least 4 weeks prior to Visit 1
• Type of inhaler: Respimat (+ HFA MDI placebo twice daily to blind for salmeterol)
• Duration of treatment: 24 weeks
Placebo (ICS alone)
• ICS type/dose: not part of randomly assigned treatment; participants continued
their medium dose of usual ICS
• Co-medications: All; participants were taking maintenance treatment with a
medium, stable dose of inhaled corticosteroids for ≥ 4 weeks before visit 1
• Type of inhaler: Respimat placebo (+ HFA MDI placebo to blind salmeterol arm)
• Duration of treatment: 24 weeks
Participants were also randomly assigned to a fourth group, salmeterol add-on, which
was not relevant to this review
Outcomes Continuous
• Trough FEV1 (L, change)
• Asthma control (ACQ)
• Trough PEF (L/min, change)
• Trough FVC (L, change)
• Quality of life (AQLQ)
• Peak FEV1 (L, change)
• Peak FVC (L, change)
Dichotomous
• Any adverse events
• All-cause serious adverse events
• Exacerbations requiring hospital admission
• Exacerbations requiring oral corticosteroids
• Asthma control (ACQ responder)
Identiﬁcation Sponsorship source: Boehringer Ingelheim
Country: USA, Brasil, China, Guatemala, India, Japan, Latvia, Mexico, Peru, Poland,
Russian Federation
29Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with
asthma (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT01172808 (Continued)
Setting: 114 Boehringer Ingelheim investigational sites in 11 countries
Comments: no publications listed; available only on manufacturer’s website and clini-
caltrials.gov
IDs: 205.418, NCT01172808
Author’s name: Boehringer Ingelheim
Institution: N/A
Email: clintriage.rdg@boehringer-ingelheim.com
Address: Boehringer Ingelheim Pharmaceuticals; 1-800-243-0127
Notes Pre-treatment: minimal baseline characteristics reported; no differences noted
TWIN trial with NCT01172821(205.419)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote from paper: “Boehringer Ingelheim
Pharma GmbH & Co KG (Biberach an
der Riss, Germany) generated the ran-
domisation list with a validated pseudo-
random number generator and a supplied
seed number. The randomisation scheme
was generated by the Boehringer Ingelheim
randomisation operator at the request of
the Boehringer Ingelheim trial statistician”
Allocation concealment (selection bias) Low risk Described as ’randomised’ on the clinical-
trials.gov record, but no details given. Pre-
vious contact with trial sponsors conﬁrmed
allocation concealment methods
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Masking described as ’double-blind’ in the
clinicaltrials.gov record
From paper: “Patients and study investi-
gators were masked to treatment alloca-
tion. Placebo devices were identical in ap-
pearance to devices containing active treat-
ments”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, double-dummy, but no spe-
ciﬁc details about outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was less than 10% in all groups,
and the full analysis set was used for all
safety and efﬁcacy analyses. “There was 1
patient in the TIO R5 group randomised
but not treated”
Number allocated to each group was given,
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as well as number completed and number
not completed with reasons for non-com-
pletion. Also number of participants used
was given for each outcome
Selective reporting (reporting bias) Low risk Study resultswere reported on clinicaltrials.
gov but did not reveal time to ﬁrst exacer-
bation, as “less than 50%of patients in each
treatment group experienced an asthma ex-
acerbation”. Numbers in each group expe-
riencing exacerbations were subsequently
reported in a peer-reviewed journal
Other bias Low risk None noted
NCT01172821
Methods Study design: randomised controlled trial
Study grouping: parallel group
Open label: no
Cluster RCT: no
Participants Baseline characteristics
LAMA add-on (low)
• N randomly assigned: 257
• N completed: 245
• Mean age, years (SD): 43.0 (12.6)
• % Male: 37.7
• % Predicted FEV1 (SD): 72.5 (8.0)
• % White: NR
• Duration of asthma, years (SD): 21.9 (14.5)
LAMA add-on (high)
• N randomly assigned: 253
• N completed: 240
• Mean age, years (SD): 44.3 (12.7)
• % Male: 42.3
• % Predicted FEV1 (SD): 72.2 (8.3)
• % White: NR
• Duration of asthma, years (SD): 23.1 (15.3)
Placebo (ICS alone)
• N randomly assigned: 254
• N completed: 240
• Mean age, years (SD): 43.0 (13.0)
• % Male: 42.9
• % Predicted FEV1 (SD): 73.0 (8.4)
• % White: NR
• Duration of asthma, years (SD): 22.0 (13.9)
Inclusion criteria: informed consent; males and females 18 to 75 years of age; ≥ 3-
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months history of asthma at enrolment; diagnosis before 40.5 years of age, conﬁrmed
by FEV1 increase ≥ 12% and ≥ 200 mL after salbutamol; on maintenance treatment
with a medium, stable dose of ICS ≥ 4 weeks; ACQ (≥ 1.5) before randomisation;
pre-bronchodilator FEV1 60% to 90% of predicted normal at screening; variation in
absolute FEV1 at screening (pre-bronchodilator) as compared with visit 2 (pre-dose)
within ± 30%; non-smoker ≥ 1 year and history < 10 pack-years; ability to use inhalers
and perform trial procedures correctly
Exclusion criteria: lungdisease or signiﬁcantmedical illness other than asthma; clinically
relevant abnormal screening, haematology or blood chemistry; hospitalisation for cardiac
failure during the past year; any unstable or life-threatening cardiac arrhythmia; known
active TB; resection, radiation or chemotherapy within 5 years for malignancy (treated
basal cell carcinoma allowed); thoracotomy with pulmonary resection; signiﬁcant alco-
hol or drug abuse within 2 years; current or recent (6 weeks) pulmonary rehabilitation;
known hypersensitivity to study drugs or to any other components of delivery systems;
pregnant or nursing women; women of childbearing potential not using effective birth
control; investigational drug, beta-blockers, tiotropium, oral or patch beta-adrenergics,
oral corticosteroids or “experimental” drugs for asthma not recommended by interna-
tional guidelines within 4 weeks; anti-IgE antibodies, e.g. omalizumab within 6 months;
cromone, methylxanthines or PDE4 inhibitors within 2 weeks; asthma exacerbation or
respiratory tract infection within 4 weeks; previous random assignment in this trial or
in the respective twin trial (NCT01172808), or current participation in another trial
Interventions Intervention characteristics
LAMA add-on (low)
• ICS type/dose: maintenance treatment with a medium, stable dose of inhaled
corticosteroids
• Add-on type/dose: tiotropium Respimat 2.5 mcg once daily
• Co-medications: LABAs, other anticholinergics, cromone, methylxanthines and
anti-IgE were not permitted. Continuation with other pre-study maintenance therapy
and rescue salbutamol was permitted
• Type of inhaler: Respimat inhaler (+ inhalation of placebo HFA MDI twice daily)
• Duration of treatment: 24 weeks
LAMA add-on (high)
• ICS type/dose: maintenance treatment with a medium, stable dose of inhaled
corticosteroids
• Add-on type/dose: tiotropium Respimat 5 mcg once daily
• Co-medications: LABAs, other anticholinergics, cromone, methylxanthines and
anti-IgE were not permitted. Continuation with other pre-study maintenance therapy
and rescue salbutamol was permitted
• Type of inhaler: Respimat inhaler (+ inhalation of placebo HFA MDI twice daily)
• Duration of treatment: 24 weeks
Placebo (ICS alone)
• ICS type/dose: maintenance treatment with a medium, stable dose of inhaled
corticosteroids
• Co-medications: LABAs, other anticholinergics, cromone, methylxanthines and
anti-IgE were not permitted. Continuation with other pre-study maintenance therapy
and rescue salbutamol was permitted
• Type of inhaler: Respimat placebo (+ HFA MDI placebo to blind salmeterol arm)
• Duration of treatment: 24 weeks
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NCT01172821 (Continued)
Participants were also randomly assigned to a fourth group, salmeterol add-on, which
was not relevant to this review
Outcomes Continuous
• Trough FEV1 (L, change)
• Asthma control (ACQ)
• Trough PEF (L/min, change)
• Trough FVC (L, change)
• Quality of life (AQLQ)
• Peak FEV1 (L, change)
• Peak FVC (L, change)
Dichotomous
• Any adverse events
• All-cause serious adverse events
• Exacerbations requiring oral corticosteroids
• Exacerbations requiring hospital admission
• Asthma control (ACQ responder)
Identiﬁcation Sponsorship source: Boehringer Ingelheim, with collaboration from Pﬁzer
Country: USA, Brasil, China, Guatemala, India, Japan, Latvia, Mexico, Peru, Poland,
Russian Federation
Setting: 125 investigational sites in 11 countries
IDs: 205.419, NCT01172821
Author’s name: Thomas B. Casale
Institution: University of South Florida
Email: casalej@ceighton.edu
Address:Morsani College of Medicine, Tampa, FL
Notes TWIN trial with NCT01172808(205.418)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote from paper: “Boehringer Ingelheim
Pharma GmbH & Co KG (Biberach an
der Riss, Germany) generated the ran-
domisation list with a validated pseudo-
random number generator and a supplied
seed number. The randomisation scheme
was generated by the Boehringer Ingelheim
randomisation operator at the request of
the Boehringer Ingelheim trial statistician”
Allocation concealment (selection bias) Low risk Previous contact with trial sponsors con-
ﬁrmed allocation concealment methods
used
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind with detailed
double-dummy placebo procedure on clin-
icaltrials.gov
From paper: “Patients and study investi-
gators were masked to treatment alloca-
tion. Placebo devices were identical in ap-
pearance to devices containing active treat-
ments”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Described as double-blind with detailed
double-dummy placebo procedure on clin-
icaltrials.gov
Incomplete outcome data (attrition bias)
All outcomes
Low risk “There was 1 patient in the TIO R2.5 and
1 patient in the TIO R5 group randomised
but not treated.” Dropout ranged between
4.7 and 6.4 across groups, and 99.8% were
included by imputation for the full analysis
set (FAS)
Number of participants allocated to each
arm of the study at the start of the study
is given, as well as the number who com-
pleted it. The number of participants who
dropped out is given, as is the reason for
non-completion of the trial. The number
of participants included in the assessment
of each outcome is also given
Selective reporting (reporting bias) Low risk Study results were reported on clinicaltri-
als.gov, but not time to ﬁrst exacerbation,
as “less than 50% of patients in each treat-
ment group experienced an asthma exac-
erbation”. Numbers in each group experi-
encing exacerbations was subsequently re-
ported in a peer-reviewed journal
Other bias Low risk None noted
NCT01316380
Methods Study design: randomised controlled trial
Study grouping: parallel group
Open label: no
Cluster RCT: no
Participants Baseline characteristics
LAMA add-on (low)
• N randomly assigned: 154
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• N completed: 149
• Mean age, years (SD): 43.8 (14.0)
• % Male: 46.75
• % Predicted FEV1 (SD): 91.3 (post BD)
• % White: 78.6
• Duration of asthma, years (SD): 17.1
LAMA add-on (high)
• N randomly assigned: 155
• N completed: 152
• Mean age, years (SD): 41.9 (13.0)
• % Male: 38.06
• % Predicted FEV1 (SD): 93.2 (post BD)
• % White: 78.7
• Duration of asthma, years (SD): 15.2
Placebo (ICS alone)
• N randomly assigned: 156
• N completed: 154
• Mean age, years (SD): 42.8 (12.1)
• % Male: 33.55
• % Predicted FEV1 (SD): 91.5 (post BD)
• % White: 76.8
• Duration of asthma, years (SD): 16.2
Inclusion criteria: informed consent; males and females 18 to 75 years of age; ≥ 3-
month history of asthma at enrolment; diagnosis of asthma before 40 years of age; pre-
BD FEV1 60% to 90% predicted normal at visit 1; variation in absolute pre-BD FEV1
values at visit 1 vs visit 2 within ± 30%; diagnosis of asthma conﬁrmed at visit 1 (or
within 2 weeks) with bronchodilator reversibility (within 10 minutes before and 15 to
30 minutes after 400 µg salbutamol/albuterol), resulting in FEV1 increase of 12% and
200 mL; symptomatic despite low doses of ICS; ACQ ≥ 1.5; low, stable ICS for ≥ 4
weeks before visit 1; never-smokers or ex-smokers ≥ 1 year and smoking history < 10
pack-years; ability to use Respimat inhaler correctly; ability to perform all trial-related
procedures, including technically acceptable pulmonary function tests, and to use the
e-Diary/peak ﬂow meter (e-Diary-compliance ≥ 80% required); if relevant, continued
use of allowed chronic pulmonary medication for entire duration of the study
Exclusion criteria: lung or additional signiﬁcant disease other than asthma, requiring
more than 10 puffs of rescue medication (salbutamol/albuterol MDI) per 24 hours on 2
consecutive days during the screening period; acute coronary syndrome (STEMI, non-
STEMI and unstable angina pectoris) within 6 months; hospitalisation for cardiac fail-
ure within 1 year; unstable or life-threatening cardiac arrhythmia, or cardiac arrhythmia
requiring intervention or a change in drug therapy within the past year; known active
TB; malignancy for which the patient has undergone resection, radiation therapy or
chemotherapy within 5 years (treated basal cell carcinoma allowed); thoracotomy with
pulmonary resection; signiﬁcant alcohol or drug abuse within 2 years; current or recent
(6 months) pulmonary rehabilitation; known hypersensitivity to anticholinergic drugs,
BAC, EDTA or any other components of the tiotropium inhalation solution; pregnant
or nursing women; patients of child-bearing potential not using highly effective methods
of birth control; treatment with beta-blocker medication, oral or patch beta-adrenergics,
systemic, i.e. oral or intravenous corticosteroids, LABA, tiotropium (Spiriva), investiga-
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tional drug, other non-approved/not recommended experimental drugs for asthma (e.
g. TNF-alpha blockers, methotrexate, cyclosporin) within 4 weeks before visit 1; topical
cardioselective beta-blocker eye medications for non-narrow angle glaucoma allowed;
depot corticosteroids within 6 months; ever treated with anti-IgE antibodies; treatment
with leukotriene modiﬁers, systemic anticholinergics, cromolyn sodium or nedocromil
sodium and methylxanthines or phosphodiesterase 4 inhibitors within 2 weeks; any
asthma exacerbation or any respiratory tract infection within 4 weeks; current participa-
tion in another trial
Interventions Intervention characteristics
LAMA add-on (low)
• ICS type/dose: maintenance treatment with a low, stable dose of inhaled
corticosteroids
• Add-on type/dose: tiotropium Respimat 2.5 mcg once daily
• Co-medications: LABAs, other anticholinergics, leukotriene modiﬁers, cromone,
methylxanthines and anti-IgE were not permitted. Continuation with other pre-study
maintenance therapy and rescue salbutamol was permitted
• Type of inhaler: Respimat inhaler
• Duration of treatment: 12 weeks
LAMA add-on (high)
• ICS type/dose: maintenance treatment with a low, stable dose of inhaled
corticosteroids
• Add-on type/dose: tiotropium Respimat 5 mcg once daily
• Co-medications: LABAs, other anticholinergics, leukotriene modiﬁers, cromone,
methylxanthines and anti-IgE were not permitted. Continuation with other pre-study
maintenance therapy and rescue salbutamol was permitted.
• Type of inhaler: Respimat inhaler
• Duration of treatment: 12 weeks
Placebo (ICS alone)
• ICS type/dose: maintenance treatment with a low, stable dose of inhaled
corticosteroids
• Co-medications: LABAs, other anticholinergics, leukotriene modiﬁers, cromone,
methylxanthines and anti-IgE were not permitted. Continuation with other pre-study
maintenance therapy and rescue salbutamol was permitted
• Type of inhaler: Respimat placebo
• Duration of treatment: 12 weeks
Outcomes Continuous
• Trough FEV1 (L, change)
• Peak FEV1 (L, change)
• Peak FVC (L, change)
Dichotomous
• Any adverse events
• All-cause serious adverse events
• Exacerbations requiring oral corticosteroids
• Exacerbations requiring hospital admission
Identiﬁcation Sponsorship source: Boehringer Ingelheim, with collaboration from Pﬁzer
Country:Argentina, Austria, Croatia, Estonia, Guatemala, Hungary, India, Italy, Korea,
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Republic of, Latvia, Poland, Slovakia
Setting: 62 Boehringer Ingelheim investigational sites in 12 countries
IDs: 205.442, 2010-023112-14, NCT01316380
Authors name: Professor P. Paggiaro
Institution: N/A
Email: clintriage.rdg@boehringer-ingelheim.com; lpaggiaro@dcap.med.unipi.it
Address: Boehringer Ingelheim Pharmaceuticals; 1-800-243-0127
Notes None
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk FromBoehringer-Ingelheim: “The sponsor
will arrange for the randomisation as well
as packaging and labelling of trial medica-
tion. The randomisation list will be gen-
erated using a validated system involving
a pseudo-random number generator and
a supplied seed number, thereby ensuring
that the resulting allocation to a treatment
is both reproducible and non-predictable”
Allocation concealment (selection bias) Low risk From Boehringer-Ingelheim: “An interac-
tive voice response system (IVRS)/ interac-
tive web response system (IWRS) will be
used for randomisation to a speciﬁc treat-
ment group in this trial and for the appro-
priate dispensation and supply of medica-
tion to patients throughout the trial”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind. Placebo admin-
istered in a matching inhaler
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No speciﬁc mention of outcome assessors,
but described as double-blind. Placebo ad-
ministered in a matching inhaler
Incomplete outcome data (attrition bias)
All outcomes
Low risk Highest dropout was reported in the tio 2.5
group at 3.2%. Very low across groups, and
all outcomes included > 98% of randomly
assigned participants. (1) Placebo started
= 156, placebo group received 1 dose =
155, placebo completed = 154, participants
analysed in each outcome = 154/155. (2)
TioR2.5 group started = 154, received at
least 1 dose = 154, completed = 149. Par-
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ticipants analysed in each outcome = 149/
151/154. (3) TioR5 group started = 155,
participants received at least 1 dose = 155,
completed = 152, participants analysed for
each outcome = 152/155. Reasons for non-
completion given
Selective reporting (reporting bias) Low risk Results for all outcomes listed in the proto-
col and on clinicaltrials.gov were uploaded
in full as described
Other bias Low risk None noted
NCT01340209
Methods Study design: Randomised controlled trial
Study grouping: parallel group
Open label: no
Cluster RCT: no
Participants Baseline characteristics
LAMA add-on (low)
• N randomly assigned: 114
• N completed: 106
• Mean age, years (SD): 44.7 (12.1)
• % Male: 36.84
• % Predicted FEV1 (SD): NR
• % White: NR
• Duration of asthma, years (SD): NR
LAMA add-on (high)
• N randomly assigned: 114
• N completed: 106
• Mean age, years (SD): 42.6 (12.8)
• % Male: 42.11
• % Predicted FEV1 (SD): NR
• % White: NR
• Duration of asthma, years (SD): NR
Placebo (ICS alone)
• N randomly assigned: 57
• N completed: 52
• Mean age, years (SD): 47.8 (13.0)
• % Male: 33.33
• % Predicted FEV1 (SD): NR
• % White: NR
• Duration of asthma, years (SD): NR
Inclusion criteria: informed consent; male and female outpatients 18 to 75 years of
age; ≥ 12-week history of asthma at enrolment; diagnosis before 40 years, conﬁrmed
by bronchodilator reversibility (15 to 30 minutes after 400 µg salbutamol), resulting in
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FEV1 increase≥ 12% and≥ 200 mL; on maintenance treatment with a medium, stable
dose of ICS (alone or in ﬁxed combination with a LABA) for ≥ 4 weeks before visit 1;
ACQ ≥ 1.5 at screening; pre-bronchodilator FEV1 60% to 90% of predicted normal
at visit 1; never-smokers or ex-smokers ≥ 1 year and smoking history < 10 pack-years;
ability to use the Respimat inhaler correctly; ability to perform all trial-related procedures
Exclusion criteria: lung or additional signiﬁcant disease other than asthma; recent his-
tory (≤ 6 months) of myocardial infarction; hospitalisation for cardiac failure within 1
year; any unstable or life-threatening cardiac arrhythmia or cardiac arrhythmia requiring
intervention, or change in drug therapywithin 1 year; known active TB;malignancy and/
or resection, radiation therapy or chemotherapy for malignancy within 5 years (treated
basal cell carcinoma allowed); undergone thoracotomy with pulmonary resection; sig-
niﬁcant alcohol or drug abuse within 2 years; known hypersensitivity to anticholinergic
drugs, benzalkonium chloride (BAC), ethylenediaminetetraacetic acid (EDTA) or any
other components of study medication delivery systems; pregnant or nursing women;
women of childbearing potential not using a highly effective method of birth control;
use of an investigational drug, beta-blocker, tiotropium (Spiriva), oral beta-adrenergics,
systemic corticosteroids, other non-approved/not guideline recommended “experimen-
tal” drugs for asthma within 4 weeks before visit 1; topical cardioselective beta-blocker
eye medications for non-narrow angle glaucoma allowed; anti-IgE antibodies, e.g. oma-
lizumab (Xolair), within 6 months before visit 1 and/or during the screening period;
any asthma exacerbation or any respiratory tract infection in the 4 weeks before visit
1 and/or during the screening period; current participation in another trial; narrow-
angle glaucoma and/or micturition disorder due to prostatic hyperplasia; < 80% eDiary
completion compliance on visit 2
Interventions Intervention characteristics
LAMA add-on (low)
• ICS type/dose: maintenance treatment with a medium, stable dose of inhaled
corticosteroids, with or without LABA
• Add-on type/dose: tiotropium Respimat 2.5 mcg once daily
• Co-medications: continuation with pre-study maintenance therapy and rescue
salbutamol permitted
• Type of inhaler: Respimat inhaler
• Duration of treatment: 52 weeks
LAMA add-on (high)
• ICS type/dose: maintenance treatment with a medium, stable dose of inhaled
corticosteroids, with or without LABA
• Add-on type/dose: tiotropium Respimat 5 mcg once daily
• Co-medications: continuation with pre-study maintenance therapy and rescue
salbutamol permitted
• Type of inhaler: Respimat inhaler
• Duration of treatment: 52 weeks
Placebo (ICS alone)
• ICS type/dose: maintenance treatment with a medium, stable dose of inhaled
corticosteroids, with or without LABA
• Co-medications: continuation with pre-study maintenance therapy and rescue
salbutamol permitted
• Type of inhaler: Respimat placebo
• Duration of treatment: 52 weeks
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Outcomes Continuous
• Trough FEV1 (L, change)
• Trough PEF (L/min, change)
• Trough FVC (L, change)
Dichotomous
• Any adverse events
• All-cause serious adverse events
• Exacerbations requiring hospital admission
Identiﬁcation Sponsorship source: Boehringer Ingelheim, with collaboration from Pﬁzer
Country: Japan
Setting: 55 Boehringer Ingelheim investigational sites in Japan
IDs: NCT01340209; 205.464
Author’s name: Boehringer Ingelheim
Institution: N/A
Email: clintriage.rdg@boehringer-ingelheim.com;
Address: Boehringer Ingelheim Pharmaceuticals; 1-800-243-0127
Notes Participants were allowed to continue taking maintenance medication, including LABA.
For this reason, the study was removed from the primary outcomes in a sensitivity
analysis. 57% of all participants continued to use a LABA during the study period
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Described as “randomised” on cinicaltri-
als.gov, wih participants randomly assigned
to placebo, LAMA add-on (low dose) and
LAMA add-on (high dose) groups at a ra-
tio of 1:2:2, respectively. Prior contact with
trial sponsors conﬁrmed that standard pro-
cedures included use of computer-gener-
ated randomisation codes
Allocation concealment (selection bias) Low risk No details given, but prior contact with
trial sponsors led to conﬁrmation the ad-
equate measures were taken for allocation
concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as “double-blind” on clinical-
trials.gov, with matching inhaler used for
placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Described as “double-blind” on clinical-
trials.gov, with matching inhaler used for
placebo
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Total dropout rate was less than 10% in all
groups. “Full analysis set: all patients of the
treated set for which baseline and at least
1 post-baseline efﬁcacy measurement were
available”. This was used for efﬁcacy mea-
sures and included > 85% of the randomly
assigned population. Numbers who started
and completed the study were given, and
reasons for discontinuation were stated for
those who did not complete the study. Also
number of participants analysed per out-
come measure is stated
Selective reporting (reporting bias) Low risk Data for all pre-speciﬁed outcomes were
available in full on clinicaltrials.gov
Other bias Low risk None noted
ACQ: Asthma Control Questionnaire; AE: adverse event; AQLQ: Asthma Quality of Life Questionnaire; HFA: hydroﬂuoroalkane;
ICS: inhaled corticosteroid; IGE: immunoglobulin E; LABA: long-acting beta2-agonst; FEV1: forced expiratory volume in 1 second;
FVC: forced vital capacity; MDI: metered-dose inhaler; NR: not reported; PEF: peak expiratory ﬂow; SAE: serious adverse event;
SD: standard deviation.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
CTRI/2008/091/000306 Too short - single dose of tiotropium
Status: not recruiting
CTRI/2012/08/002915 Wrong comparator
Status: not recruiting
EUCTR2006-003385-34-NL Too short
Status: authorised
JPRN-UMIN000003618 Wrong participant population (COPD, not asthma)
Status: not recruiting
JPRN-UMIN000005459 Wrong participant population (COPD, not asthma)
Status: not recruiting
JPRN-UMIN000010352 Too short - single dose of tiotropium
Status: not recruiting
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Kerstjens 2012 LABA included as part of the randomly assigned treatment, or ICS/LABA combination therapy
required for inclusion
NCT00546234 Wrong comparator
NCT00557180 Wrong study design - observational
Status: not recruiting
NCT00557700 Too short
NCT00706446 Wrong comparator
NCT00772538 LABA included as part of the randomly assigned treatment, or ICS/LABA combination therapy
required for inclusion
NCT00776984 LABA included as part of the randomly assigned treatment, or ICS/LABA combination therapy
required for inclusion
NCT01290874 Wrong comparator
NCT01573624 Too short
NCT01641692 Too short
NCT01696214 Wrong comparator
NCT02066298 Wrong intervention
NCT02127697 LABA included as part of the randomly assigned treatment, or ICS/LABA combination therapy
required for inclusion
Vogelberg 2014 Wrong participant population - adolescents
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D A T A A N D A N A L Y S E S
Comparison 1. LAMA add-on vs ICS alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Exacerbations requiring oral
corticosteroids
3 2277 Odds Ratio (M-H, Random, 95% CI) 0.65 [0.46, 0.93]
2 Quality of life (AQLQ) 3 1713 Mean Difference (IV, Random, 95% CI) 0.05 [-0.03, 0.12]
3 All-cause serious adverse events 5 2562 Odds Ratio (M-H, Random, 95% CI) 0.60 [0.23, 1.57]
4 Exacerbations requiring hospital
admission
5 2562 Odds Ratio (M-H, Random, 95% CI) 0.42 [0.12, 1.47]
5 Trough FEV1 (litres, change
from baseline)
5 2459 Mean Difference (IV, Random, 95% CI) 0.14 [0.10, 0.17]
6 Peak FEV1 (litres, change from
baseline)
3 1923 Mean Difference (IV, Random, 95% CI) 0.19 [0.15, 0.23]
7 Trough PEF (litres/min, change
from baseline)
5 2456 Mean Difference (IV, Random, 95% CI) 28.07 [22.51, 33.64]
8 Trough FVC (litres, change from
baseline)
4 2002 Mean Difference (IV, Random, 95% CI) 0.09 [0.05, 0.13]
9 Peak FVC (litres, change from
baseline)
3 1922 Mean Difference (IV, Random, 95% CI) 0.11 [0.08, 0.15]
10 Asthma control (ACQ) 3 1916 Mean Difference (IV, Random, 95% CI) -0.08 [-0.19, 0.03]
11 Asthma control (ACQ
’responder’)
3 2009 Odds Ratio (M-H, Random, 95% CI) 1.23 [0.87, 1.74]
12 Any adverse events 5 2562 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.80, 1.14]
13 Adverse events classiﬁed as
asthma
5 2561 Odds Ratio (M-H, Random, 95% CI) 0.85 [0.69, 1.05]
Comparison 2. Subgroup analyses
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause serious adverse events -
by study duration
5 2562 Odds Ratio (M-H, Random, 95% CI) 0.60 [0.23, 1.57]
1.1 ≤ 6 months 4 2277 Odds Ratio (M-H, Random, 95% CI) 0.87 [0.37, 2.05]
1.2 > 6 months 1 285 Odds Ratio (M-H, Random, 95% CI) 0.19 [0.07, 0.53]
2 Exacerbations requiring oral
corticosteroids - by Respimat
dose
3 2277 Odds Ratio (M-H, Random, 95% CI) 0.66 [0.46, 0.93]
2.1 Respimat 2.5 mcg 2 1012 Odds Ratio (M-H, Random, 95% CI) 0.53 [0.29, 0.95]
2.2 Respimat 5 mcg 3 1265 Odds Ratio (M-H, Random, 95% CI) 0.74 [0.48, 1.15]
3 Quality of life (AQLQ) - by
Respimat dose
3 1713 Mean Difference (IV, Random, 95% CI) 0.05 [-0.03, 0.12]
3.1 Respimat 2.5 mcg 2 734 Mean Difference (IV, Random, 95% CI) 0.04 [-0.08, 0.16]
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3.2 Respimat 5 mcg 3 979 Mean Difference (IV, Random, 95% CI) 0.05 [-0.05, 0.15]
4 All-cause serious adverse events -
by Respimat dose
5 2717 Odds Ratio (M-H, Random, 95% CI) 0.55 [0.30, 1.03]
4.1 Respimat 2.5 mcg 5 1487 Odds Ratio (M-H, Random, 95% CI) 0.58 [0.22, 1.50]
4.2 Respimat 5 mcg 4 1230 Odds Ratio (M-H, Random, 95% CI) 0.54 [0.21, 1.43]
5 All-cause serious adverse events -
by ICS dose
5 2562 Odds Ratio (M-H, Fixed, 95% CI) 0.59 [0.35, 1.00]
5.1 Low-dose ICS 1 464 Odds Ratio (M-H, Fixed, 95% CI) 0.5 [0.03, 8.05]
5.2 Medium-dose ICS 4 2098 Odds Ratio (M-H, Fixed, 95% CI) 0.60 [0.35, 1.01]
Comparison 3. Respimat 2.5 mcg vs 5 mcg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Exacerbations requiring oral
corticosteroids
2 1345 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.29, 3.14]
2 Quality of life (AQLQ) 2 973 Mean Difference (IV, Random, 95% CI) 0.00 [-0.09, 0.10]
3 All-cause serious adverse events 4 1573 Odds Ratio (M-H, Random, 95% CI) 1.01 [0.50, 2.02]
A D D I T I O N A L T A B L E S
Table 1. Summary characteristics of included studies
Study ID Country Total N Duration
(weeks)
Blinding Randomly
assigned groups
Age (mean, y) % pred FEV1
NCT00350207
International 254 16 DB, DD 1) Tiotropium
Respimat 5 mcg
daily
2) Placebo (ICS
alone)
43.5
44.0
74.1
75.3
NCT01172808
International 795 24 DB, DD 1) Tiotropium
Respimat 2.5mcg
daily
2) Tiotropium
Respimat 5 mcg
daily
3) Placebo (ICS
alone)
43.7
44.4
42.5
73.1
72.2
73.0
NCT01172821
International 764 24 DB, DD 1) Tiotropium
Respimat 2.5mcg
daily
2) Tiotropium
Respimat 5 mcg
43.0
44.3
43.0
72.5
72.2
73.0
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Table 1. Summary characteristics of included studies (Continued)
daily
3) Placebo (ICS
alone)
NCT01316380
International 465 12 DB, DD 1) Tiotropium
Respimat 2.5mcg
daily
2) Tiotropium
Respimat 5 mcg
daily
3) Placebo (ICS
alone)
43.8
41.9
42.8
91.3*
93.2
91.5
NCT01340209
Japan 285 52 DB, DD 1) Tiotropium
Respimat 2.5mcg
daily
2) Tiotropium
Respimat 5 mcg
daily
3) Placebo (ICS
alone)
44.7
42.6
47.8
N/R
N/R
N/R
Total N is the number randomly assigned to the groups of interest for this review. Age and % predicted FEV1 are presented as mean
values.
DB = double-blind; DD = double-dummy; NR = not reported; OL = open label.
* Values here are post-bronchodilator.
C O N T R I B U T I O N S O F A U T H O R S
Debbie Allison wrote the Background, and Kayleigh Kew wrote the Methods, each with critical input from the other review author.
Debbie and Kayleigh extracted data, Kayleigh constructed the analyses and both contributed to preparation of a draft. All review
authors provided critical input on the ﬁnal version of the review.
D E C L A R A T I O N S O F I N T E R E S T
Debbie Allison: none known.
Kayleigh Kew: none known.
Anne Boyter: none known.
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S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute of Health Research, UK.
Evidence to guide care in adults and children with asthma, 13/89/14
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We used Covidence for sifting and extracting study characteristics and outcome data. We were not able to pool more than 10 trials, so
we could not prepare a funnel plot to explore possible small-study and publication biases.
We performed an additional sensitivity analysis after excluding the trial in which 57% of participants were taking LABA combined
with the study medication.
We analysed data for an additional outcome, ’Adverse events classiﬁed as asthma’, because the preferred data for ’Exacerbations requiring
oral corticosteroids’ were not available in most trials.
We included no cross-over studies, but had we found any, we would have analysed data from cross-over trials using generic inverse
variance (GIV) and only results derived from paired analyses.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Inhalation; Adrenal Cortex Hormones [∗administration & dosage; adverse effects]; Anti-Asthmatic Agents
[∗administration & dosage; adverse effects]; Asthma [∗drug therapy]; Disease Progression; Drug Therapy, Combination [methods];
Muscarinic Antagonists [∗administration & dosage; adverse effects]; Quality of Life; Randomized Controlled Trials as Topic
MeSH check words
Adult; Female; Humans; Male
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